Details

Autor(en) / Beteiligte

• Vaucher, Yvonne E
• Peralta-Carcelen, Myriam
• Finer, Neil N
• Carlo, Waldemar A
• Gantz, Marie G
• Walsh, Michele C
• Laptook, Abbot R
• Yoder, Bradley A
• Faix, Roger G
• Das, Abhik
• Schibler, Kurt
• Rich, Wade
• Newman, Nancy S
• Vohr, Betty R
• Yolton, Kimberly
• Heyne, Roy J
• Wilson-Costello, Deanne E
• Evans, Patricia W
• Goldstein, Ricki F
• Acarregui, Michael J
• Adams-Chapman, Ira
• Pappas, Athina
• Hintz, Susan R
• Poindexter, Brenda
• Dusick, Anna M
• McGowan, Elisabeth C
• Ehrenkranz, Richard A
• Bodnar, Anna
• Bauer, Charles R
• Fuller, Janell
• O'Shea, T. Michael
• Myers, Gary J
• Higgins, Rosemary D

Titel

Neurodevelopmental Outcomes in the Early CPAP and Pulse Oximetry Trial

Ist Teil von

• The New England journal of medicine, 2012-12, Vol.367 (26), p.2495-2504

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2012

Quelle

MEDLINE

Beschreibungen/Notizen

• This multicenter trial showed no significant differences in the composite outcome of death or neurodevelopmental impairment among extremely preterm infants randomly assigned to early CPAP or early surfactant and to lower or higher oxygen saturation. Extremely premature infants are at high risk for death and neurosensory or developmental impairment in early childhood. 1 – 3 The risk of neurodevelopmental impairment increases with decreasing gestational age and greater severity of illness. Neurodevelopmental impairment is often a consequence of neonatal complications. 4 – 12 Although surfactant administration decreases the risk of death and bronchopulmonary dysplasia, randomized, controlled trials of various respiratory interventions have not shown significant reductions in mortality and morbidity or improvement in developmental outcomes. 13 – 17 We previously reported results of the multicenter, randomized, controlled Surfactant, Positive Pressure, and Pulse Oximetry Randomized Trial (SUPPORT), which involved extremely premature infants (from . . .